v3.25.2
SEGMENT INFORMATION
 6 Months Ended
Jun. 30, 2025
Segment Reporting [Abstract]  
SEGMENT INFORMATION

NOTE 9: SEGMENT INFORMATION

 

The Company operates in one business segment, focusing on the development of a novel and patented systemically administered anti-cancer and anti-viral immunotherapy. The Company’s chief operating decision maker (“CODM”) is the chief executive officer. The CODM assesses performance for the segment based on operating expenses as reported in the accompanying interim consolidated statements of operations.

 

As such, the CODM uses cash forecast models in deciding how to invest into the segment. Such cash forecast models are reviewed to assess the entity-wide operating results and performance. Net loss is used to monitor budget versus actual results. Monitoring budgeted versus actual results is used in assessing performance of the segment.

 

The following table presents reportable segment loss, including significant expenses regularly provided to the CODM, attributable to the Company’s reportable segment for the periods presented:

  

$1   $2   $3   $4 
   Three months ended   Six months ended 
   June 30   June 30 
   2025   2024   2025   2024 
Research and development:                    
External research and development  $1,687,877   $923,864   $4,003,989   $1,704,764 
Internal personnel costs   479,237    790,109    973,965    1,600,351 
Total research and development   2,167,114    1,713,973    4,977,954    3,305,115 
General and administrative   2,289,649    2,394,912    4,051,368    4,747,009 
Other income, net   (15,547)   (93,618)   (55,676)   (230,180)
Change in fair value of convertible promissory notes   787,703    -    787,703    - 
Net loss  $5,228,919   $4,015,267   $9,761,349   $7,821,944